Park Avenue Securities LLC Cuts Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Park Avenue Securities LLC cut its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 42.6% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,003 shares of the specialty pharmaceutical company’s stock after selling 2,233 shares during the period. Park Avenue Securities LLC’s holdings in Jazz Pharmaceuticals were worth $362,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of JAZZ. Wedmont Private Capital acquired a new position in shares of Jazz Pharmaceuticals during the first quarter worth about $214,000. Perpetual Ltd lifted its stake in Jazz Pharmaceuticals by 54.0% in the first quarter. Perpetual Ltd now owns 475,018 shares of the specialty pharmaceutical company’s stock worth $57,202,000 after acquiring an additional 166,543 shares during the last quarter. Alaska Permanent Fund Corp grew its holdings in Jazz Pharmaceuticals by 9.2% during the 1st quarter. Alaska Permanent Fund Corp now owns 20,540 shares of the specialty pharmaceutical company’s stock worth $2,473,000 after acquiring an additional 1,739 shares in the last quarter. Rise Advisors LLC increased its position in shares of Jazz Pharmaceuticals by 2,255.6% in the 1st quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company’s stock valued at $26,000 after purchasing an additional 203 shares during the last quarter. Finally, Centre Asset Management LLC acquired a new stake in shares of Jazz Pharmaceuticals in the 1st quarter valued at $8,475,000. 89.14% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

JAZZ has been the subject of a number of analyst reports. Needham & Company LLC lowered their target price on shares of Jazz Pharmaceuticals from $222.00 to $210.00 and set a “buy” rating for the company in a research note on Thursday, June 20th. Truist Financial reiterated a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, March 20th. Cantor Fitzgerald restated an “overweight” rating and set a $180.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, April 10th. Piper Sandler increased their price target on shares of Jazz Pharmaceuticals from $171.00 to $188.00 and gave the company an “overweight” rating in a research note on Wednesday, March 20th. Finally, HC Wainwright restated a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research report on Friday, May 3rd. Two investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $190.00.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 5,000 shares of the firm’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $109.65, for a total value of $548,250.00. Following the completion of the sale, the executive vice president now owns 36,629 shares of the company’s stock, valued at $4,016,369.85. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 4.20% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Stock Down 0.3 %

Shares of NASDAQ:JAZZ opened at $106.73 on Monday. Jazz Pharmaceuticals plc has a fifty-two week low of $103.01 and a fifty-two week high of $146.70. The company has a quick ratio of 1.90, a current ratio of 2.27 and a debt-to-equity ratio of 1.38. The firm’s 50-day simple moving average is $108.93 and its 200-day simple moving average is $116.67. The company has a market cap of $6.73 billion, a price-to-earnings ratio of 22.01, a PEG ratio of 1.64 and a beta of 0.62.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 earnings per share for the quarter, missing analysts’ consensus estimates of $3.53 by ($1.55). The business had revenue of $901.98 million during the quarter, compared to analysts’ expectations of $938.99 million. Jazz Pharmaceuticals had a net margin of 8.61% and a return on equity of 27.86%. As a group, equities research analysts predict that Jazz Pharmaceuticals plc will post 15.35 earnings per share for the current year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.